Ocugen Skyrockets On $23M Capital Raise Issued At 46% Premium

  • Ocugen Inc (NASDAQ: OCGN) rises sharply after announcing the sale of 3 million common shares at $7.65 per share in a registered direct offering, with gross proceeds of $23 million. The offer price represents a premium of 46% on the last close price of $5.25 on Friday.
  • The offering is expected to close on or about February 10.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • See also: Best Biotech Stocks Right Now
  • Ocugen expects to use the proceeds for general corporate purposes, capital expenditures, working capital, and general and administrative expenses.
  • Ocugen and Bharat Biotech entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech's Covaxin, an advanced stage whole-virion inactivated Covid-19 vaccine candidate, for the U.S. market.
  • Last week, the stock rallied on an upgrade from H.C. Wainwright from neutral to buy and a $4.50 price forecast. The analyst cheered Ocugen's recent deal with India-based vaccine developer Bharat Biotech to potentially bring Covaxin, a COVID-19 vaccine candidate, to the U.S. market. Ocugen will retain 45% of the profits. In December last, both the parties had signed a binding letter of intent to co-develop Covaxin for the U.S market. 
  • Price Action: OCGN soared as much as 71% at $8.96 in the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsOfferingsSmall CapGeneralBharat BiotechCovaxinCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!